Research output per year
Research output per year
Personal profile
Professional Information
I am medical oncologist trained in Chile and formally trained again at the National Cancer Institute National Institutes of Health, Bethesda MD, obtaining my second oncology fellowship. Additionally, I have received direct lung cancer training from prestigious investigators such as Guiseppe Giacconne MD and medical Oncology mentorship by Antonio Fojo.
Research Interests
My main interest are immuno-oncology specific diseases such as lung cancer, renal cancer and melanoma and areas in medicine like Health policy and biostatistics.
I was editor of the Seminar in Oncology journal and currently I am one of the editors of Journal of Thoracic Oncology.
I have participated in more than 50 publications in indexed journals and have written several medical oncology books chapters.
I am also the Medical Director of the Cancer Center of Clínica Universidad de los Andes and the Medical Director of Bradford Hill clinical research center and have participated as principal investigator in more than 30 cancer clinical trials.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
External positions
Medical Director, Bradford Hill Clinical Research Center.
1 Mar 2019 → …
Fingerprint
Dive into the research topics where Mauricio Burotto is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Motzer, R. J., McDermott, D. F., Escudier, B., Burotto, M., Choueiri, T. K., Hammers, H. J., Barthélémy, P., Plimack, E. R., Porta, C., George, S., Powles, T., Donskov, F., Gurney, H., Kollmannsberger, C. K., Grimm, M. O., Barrios, C., Tomita, Y., Castellano, D., Grünwald, V., Rini, B. I., & 5 others, 1 Jun 2022, In: Cancer. 128, 11, p. 2085-2097 13 p.Research output: Contribution to journal › Article › peer-review
Open Access7 Scopus citations -
Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP)
Cardona, A. F., Ruiz-Patiño, A., Recondo, G., Martín, C., Raez, L., Samtani, S., Minata, J. N., Blaquier, J. B., Enrico, D., Burotto, M., Ordóñez-Reyes, C., Chamorro, D. F., Garcia-Robledo, J. E., Corrales, L., Zatarain-Barrón, Z. L., Más, L., Sotelo, C., Ricaurte, L., Santoyo, N., Cuello, M., & 19 others, 2022, (Accepted/In press) In: Clinical Lung Cancer.Research output: Contribution to journal › Article › peer-review
-
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial
Motzer, R. J., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Shah, A. Y., Suárez, C., Hamzaj, A., Porta, C., Hocking, C. M., Kessler, E. R., Gurney, H., Tomita, Y., Bedke, J., Zhang, J., Simsek, B., Scheffold, C., Apolo, A. B. & Choueiri, T. K., Jul 2022, In: The Lancet Oncology. 23, 7, p. 888-898 11 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)
Cordeiro de Lima, V. C., Corassa, M., Saldanha, E., Freitas, H., Arrieta, O., Raez, L., Samtani, S., Ramos, M., Rojas, C., Burotto, M., Chamorro, D. F., Recondo, G., Ruiz-Patiño, A., Más, L., Zatarain-Barrón, L., Mejía, S., Nicolas Minata, J., Martín, C., Bautista Blaquier, J., Motta Guerrero, R., & 21 others, Aug 2022, In: Lung Cancer. 170, p. 114-121 8 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma
Geynisman, D. M., Burotto, M., Porta, C., Suarez, C., Bourlon, M. T., Huo, S., Del Tejo, V., Du, E. X., Yang, X., Betts, K. A., Choueiri, T. K. & McGregor, B., 2022, (Accepted/In press) In: Clinical Drug Investigation.Research output: Contribution to journal › Article › peer-review
Open Access
Press / Media
-
-
Chile is the first Latin American country to obtain "intelligent home" technology
11/12/21
1 item of Media coverage
Press/Media
-
Does cytoreductive nephrectomy remain an essential component of care for advanced renal cell carcinoma?
25/06/19
1 item of Media coverage
Press/Media
-
New technique facilitates tumor detection and avoids intervention
4/06/18
1 item of Media coverage
Press/Media
-
Recurrent Respiratory Papillomatosis and Bevacizumab Treatment
2/10/17
1 item of Media coverage
Press/Media